Every service at canBwell is grounded in a body of clinical research — from large randomized controlled trials to systematic reviews and meta-analyses. Below is a curated overview of major studies relevant to our offerings, organized by service area, with links to the original sources.
rTMS for Depression & Mood
rTMS is FDA-cleared for treatment-resistant depression and has one of the largest clinical trial bases of any neuromodulation technique, including landmark government-funded multisite studies.
A 190-patient, NIMH-funded randomized controlled trial found that daily rTMS to the left prefrontal cortex, used as a drug-free standalone treatment, produced a remission rate roughly four times higher than sham stimulation. This trial was a key piece of evidence supporting FDA clearance of rTMS for major depressive disorder in 2008.
In a 240-participant randomized clinical trial, combining active rTMS with active tDCS produced a significantly greater reduction in depression scores after two weeks than either technique alone or sham treatment — suggesting combined neuromodulation protocols may offer faster results with a comparable safety profile to either treatment individually.
In a 12-month randomized trial of 281 patients in remission from depression, those receiving rTMS — alone or alongside antidepressants — had substantially lower relapse and recurrence rates (16–24%) than those on antidepressants alone (44%), without an increased risk of manic episodes. This supports the use of rTMS as a maintenance strategy, not just an acute treatment.
The FDA's regulatory guidance outlines the study design standards (randomized, double-blind, sham-controlled, multicenter) required to support clearance of rTMS devices for depression, and mandates clear reporting of side effects such as headache and application-site pain. This document reflects the regulatory rigor behind rTMS as a cleared medical device category.
tDCS for Mood & Cognition
tDCS has an expanding evidence base across mood disorders, cognitive impairment, and neurological conditions, with meta-analyses identifying the stimulation parameters most associated with benefit.
A meta-analysis of 23 studies found that tDCS significantly improved overall cognition — particularly executive function and language — with the strongest effects at 2 mA intensity, sessions of 25 minutes or longer, and a minimum of 10 sessions. The same protocols were also associated with reduced depressive mood, supporting parameter-based protocol design.
This large meta-analysis evaluated both TMS and tDCS for cognitive outcomes across schizophrenia, depression, dementia, Parkinson's disease, stroke, traumatic brain injury, and multiple sclerosis. Both techniques showed small but statistically significant improvements in working memory, with age positively influencing the effect of TMS — useful context for setting realistic expectations.
A 2025 systematic review of 22 studies found that tDCS significantly enhanced cognitive function, reduced anxiety and depression, and improved several sleep measures — including sleep duration, sleep efficiency, and daytime sleepiness — in people with Parkinson's disease. The findings support tDCS as an adjunct for mood and sleep regulation, not just motor symptoms.
This systematic review and meta-analysis evaluated tDCS for depressive and anxiety symptoms across multiple clinical diagnoses, finding consistent therapeutic effects that generalized across different conditions rather than being limited to a single diagnosis — supporting tDCS as a broadly applicable mood-regulation tool when paired with appropriate clinical assessment.
Neurofeedback for Attention & Self-Regulation
The largest evidence base for neurofeedback is in ADHD, where multiple meta-analyses of randomized controlled trials have evaluated its effects on attention, hyperactivity, and impulsivity.
A network meta-analysis spanning 13 studies and 1,370 children aged 5–11 found that most neurofeedback protocols outperformed placebo for ADHD symptoms. Several specific protocols — including SMR training, slow cortical potential training, and theta/beta ratio training — also showed strong acceptability among young participants, supporting their use as part of a child-centred treatment plan.
This review pooled 17 randomized controlled trials covering 1,211 children and adolescents with ADHD, using the most rigorous "most-proximal-rater" outcome standard (i.e., the person closest to the child's daily behaviour). The analysis found measurable improvement in core ADHD symptoms, supporting neurofeedback as a viable non-pharmacological option.
A meta-analysis of 10 studies covering 539 participants found a small-to-medium improvement in inhibitory control following neurofeedback training, with no evidence of publication bias. Notably, longer-term training protocols — more than 21 hours of total training — showed stronger effects, suggesting that consistency and total "dose" of training matter for outcomes.
This systematic review and meta-analysis investigated whether EEG-neurofeedback adds benefit on top of standard ADHD medication. Drawing on RCTs from major databases, the analysis examined changes in global, inattentive, and hyperactive/impulsive symptom scores — relevant for clients who want to explore complementary, non-pharmacological additions to an existing treatment plan.
PBM for Cognitive Function
Research on transcranial near-infrared light therapy spans healthy aging, mild cognitive impairment, and neurodegenerative conditions, with consistent findings around mitochondrial and cognitive effects.
In a sham-controlled pilot trial, 20 adults aged 50+ with mild cognitive impairment received either active or sham transcranial photobiomodulation (810nm light, 20 minutes/session). Compared to sham, the active group showed improved global cognition and episodic memory, along with favourable shifts in metabolic markers and increased brain network connectivity — an encouraging multimodal result for a non-invasive, well-tolerated intervention.
In this randomized controlled trial, 42 older women with mild cognitive impairment received either real or sham photobiomodulation across 5 sessions targeting the right frontal cortex. The active group showed measurable improvements on cognitive testing (MMSE) and an attention-based Go/No-Go task, supporting PBM's role in supporting attentional and cognitive performance in an aging population.
This comprehensive review covers the cellular mechanism behind PBM — near-infrared light is absorbed by mitochondrial cytochrome c oxidase, boosting ATP production and cellular repair processes. It surveys clinical trials across traumatic brain injury, stroke, Alzheimer's, Parkinson's, and depression, including the large NeuroThera stroke trials involving over 1,400 participants, and notes growing interest in PBM for cognitive enhancement in healthy adults.
This ongoing pilot trial is testing whether transcranial PBM improves "neurovascular coupling" — the brain's ability to direct blood flow to active regions — in both younger and older adults, and whether any improvement translates into better memory and motor task performance, alongside reduced markers of brain inflammation and oxidative stress.
Biofeedback for Stress & Regulation
Heart rate variability biofeedback has one of the more established evidence bases among self-regulation techniques, with multiple meta-analyses across anxiety, depression, and stress-related conditions.
This meta-analysis pooled 14 randomized controlled trials covering 794 participants and found a medium effect size for HRV biofeedback in reducing depressive symptoms. The authors note that prior reviews had established similar effects for anxiety and stress, positioning HRV biofeedback as a versatile, low-risk tool across several common mental health concerns.
This review synthesizes randomized studies of HRV biofeedback and concludes that its efficacy is mild to moderate across a range of outcomes — including anxiety, anger regulation, and cardiovascular health markers — describing it as a strong complementary intervention for health, medical, educational, and sport-performance settings.
In this randomized controlled trial, 50 women completed a 5-week HRV biofeedback program with weekly sessions and daily home practice. The intervention group showed statistically significant improvements in psychological well-being across all participants, with an additional significant reduction in anxiety specifically among pregnant participants — supporting its use as a gentle, accessible stress-reduction tool.
A three-armed randomized trial of 60 women with a history of primary breast cancer tested a 4-week, smartphone-based HRV biofeedback program involving daily paced breathing. The intervention group showed measurable increases in HRV and long-lasting improvements in sleep quality compared to waitlist controls — relevant for clients managing stress-related sleep disruption following major health events.
IV Vitamin C, NAD+ & Cellular Wellness
IV nutrient therapy draws on pharmacokinetic research showing that intravenous delivery achieves plasma concentrations not possible with oral supplementation, alongside emerging clinical research on specific compounds like NAD+.
This landmark pharmacokinetic study established that intravenous vitamin C produces plasma ascorbate concentrations far exceeding what oral supplementation can achieve, even at high oral doses. This finding underpins the clinical rationale for IV delivery in contexts where higher plasma vitamin C levels are the goal, and is widely cited across subsequent IV nutrient research.
This meta-analysis of randomized controlled trials examined IV vitamin C monotherapy in critically ill patients, finding an association with reduced overall mortality — particularly in more severely ill patient subgroups. While conducted in a critical care context rather than wellness, it provides safety and dosing data (450–24,000 mg/day) relevant to understanding the physiological effects of IV vitamin C.
This pilot study tracked changes in plasma and urine NAD+ and its metabolites during and after a 6-hour intravenous NAD+ infusion. It found that plasma NAD+ levels did not rise until roughly 2 hours into the infusion, providing early human pharmacokinetic data that has informed the design of subsequent NAD+ IV protocols and dosing schedules.
This retrospective review of electronic medical records from a commercial wellness setting compared IV NAD+ to IV nicotinamide riboside (NR) over four consecutive days of infusions with 30-day follow-up, evaluating infusion time, tolerability, and safety markers. As one of the few studies examining IV NAD+ as commonly administered in clinical wellness settings, it offers practical safety context — though the authors note that controlled trials directly evaluating clinical or wellness outcomes of IV NAD+ remain limited.
Acupuncture for Chronic Pain
Acupuncture has one of the deepest research libraries of any complementary modality, with decades of systematic reviews focused on chronic pain conditions including low back pain, sciatica, and pelvic pain.
This systematic review and meta-analysis pooled 11 randomized controlled trials covering 868 participants with chronic sciatica caused by herniated discs, evaluating leg pain intensity and functional mobility. The analysis compared acupuncture against sham acupuncture, standard care, and conventional treatment, providing one of the most current evidence syntheses for this specific pain condition.
This PRISMA-registered systematic review focused exclusively on randomized trials comparing acupuncture against well-defined usual care for chronic low back pain lasting 12+ weeks, separately analyzing immediate (within 2 weeks) and intermediate (2 weeks–6 months) effects on pain and disability — offering a clearer picture of how quickly benefits may emerge and how long they last.
This review evaluated randomized controlled trials of acupuncture for chronic pain published between 2000 and 2018, applying updated reporting standards (STRICTA) to assess study quality. It highlights the importance of control-group design — including sham acupuncture — in interpreting results, and remains a key methodological reference for understanding the strength of acupuncture evidence.
This meta-analysis evaluated 17 studies covering 1,455 patients with chronic pelvic pain, pooling outcomes from validated pain scales. It also references related meta-analyses showing acupuncture's effectiveness for postoperative pain, myofascial pain, cancer-related pain, and primary dysmenorrhea — illustrating the breadth of pain conditions where acupuncture has been studied.
CBT, EMDR & Trauma-Focused Therapy
Cognitive behavioral therapy and trauma-focused approaches like EMDR are among the most extensively researched psychotherapy modalities, with decades of randomized controlled trials and meta-analyses across anxiety, depression, and PTSD.
This widely-cited meta-analysis pooled 41 randomized placebo-controlled trials covering 2,843 participants with generalized anxiety disorder, OCD, panic disorder, PTSD, social anxiety, and acute stress disorder. CBT showed moderate effects on target symptoms and smaller but meaningful effects on co-occurring depression and quality of life, with response rates roughly three times higher than placebo.
This updated meta-analysis focused specifically on placebo-controlled trials published since 2017, finding continued — though modest — benefits of CBT for anxiety-related symptoms. The authors note that more recent effect sizes appear smaller than in earlier meta-analyses, an important nuance for setting realistic expectations about treatment timelines and outcomes.
This overview evaluated 22 systematic reviews and meta-analyses on EMDR (Eye Movement Desensitization and Reprocessing) for adults with PTSD. The pooled evidence suggests EMDR meaningfully reduces PTSD symptoms compared to inactive controls like waitlists, and performs comparably to other established trauma-focused therapies such as trauma-focused CBT — though the authors note that certainty of evidence varies from low to very low across reviews.
This early meta-analysis pooled 26 randomized controlled trials of EMDR published between 1991 and 2013, evaluating effects on PTSD, depression, anxiety, and subjective distress. A notable finding was that sessions longer than 60 minutes were associated with significantly greater reductions in both anxiety and depression compared to shorter sessions — practical information for session-length planning.
How We Use This Research
Large randomized controlled trials and meta-analyses carry more weight than pilot studies or single trials. We note study size and design so you can weigh the evidence appropriately.
A study finding an average effect across a group doesn't guarantee the same result for any one person. Your clinical assessment determines what's appropriate for you specifically.
Some areas — like IV NAD+ — have more commercial use than completed controlled trials. We're transparent about where evidence is still developing versus well-established.
Our clinical team is happy to discuss the research behind any service and how it relates to your specific goals and health history. Start with a free consult — no commitment to a specific treatment.
